[go: up one dir, main page]

MX2023005078A - Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. - Google Patents

Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.

Info

Publication number
MX2023005078A
MX2023005078A MX2023005078A MX2023005078A MX2023005078A MX 2023005078 A MX2023005078 A MX 2023005078A MX 2023005078 A MX2023005078 A MX 2023005078A MX 2023005078 A MX2023005078 A MX 2023005078A MX 2023005078 A MX2023005078 A MX 2023005078A
Authority
MX
Mexico
Prior art keywords
kras
crystalline forms
inhibitor compound
new crystalline
pharmaceutical composition
Prior art date
Application number
MX2023005078A
Other languages
English (en)
Inventor
Andrea Vaupel
Rainer Machauer
Marc Gerspacher
Stefan Stutz
Edwige Liliane Jeanne Lorthiois
Bo Liu
Simona Cotesta
Catherine Leblanc
Robert Mah
Heng Ge
Rainer Wilcken
Christophe Mura
Pascal Rigollier
Nadine Schneider
Nicolas Warin
Tanja Meister
Lijun Xue
Marie- Anne Lozac'h
Ross Sinclair Strang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2020/125425 external-priority patent/WO2021120890A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023005078A publication Critical patent/MX2023005078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan formas cristalinas de un compuesto inhibidor de KRAS G12C y procesos para su preparación. Asimismo, se proporciona una composición farmacéutica que comprende dichas formas cristalinas, y al menos un excipiente farmacéuticamente aceptable. La composición farmacéutica se puede usar como un medicamento, en particular para el tratamiento del cáncer, y del cáncer asociado con la mutación KRAS G12C.
MX2023005078A 2020-10-30 2021-10-29 Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. MX2023005078A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2020/125425 WO2021120890A1 (en) 2019-12-20 2020-10-30 Pyrazolyl derivatives useful as anti-cancer agents
PCT/IB2020/062144 WO2021124222A1 (en) 2019-12-20 2020-12-17 Pyrazolyl derivatives useful as anti-cancer agents
CN2021101813 2021-06-23
PCT/CN2021/127601 WO2022089604A1 (en) 2020-10-30 2021-10-29 New crystalline forms of a kras g12c inhibitor compound

Publications (1)

Publication Number Publication Date
MX2023005078A true MX2023005078A (es) 2023-05-16

Family

ID=81383573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005078A MX2023005078A (es) 2020-10-30 2021-10-29 Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.

Country Status (12)

Country Link
US (1) US20240116900A1 (es)
EP (1) EP4237412A4 (es)
JP (1) JP2023547194A (es)
KR (1) KR20230098252A (es)
CN (1) CN116472039A (es)
AU (1) AU2021372796A1 (es)
BR (1) BR112023007912A2 (es)
CA (1) CA3199295A1 (es)
IL (1) IL302359A (es)
MX (1) MX2023005078A (es)
TW (1) TW202233607A (es)
WO (1) WO2022089604A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
EP4217071A1 (en) 2020-09-23 2023-08-02 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2025203012A1 (en) 2024-03-27 2025-10-02 Novartis Ag Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
WO2025202971A1 (en) 2024-03-27 2025-10-02 Novartis Ag Kras g12c inhibitor for use for the treatment of non-small cell lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
CN101815712A (zh) * 2007-08-01 2010-08-25 辉瑞有限公司 吡唑化合物及其作为raf抑制剂的用途
BRPI0916356B1 (pt) * 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
CN103153980B (zh) * 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
KR20160076519A (ko) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
TW201817726A (zh) * 2016-11-14 2018-05-16 大陸商江蘇恆瑞醫藥股份有限公司 ３，４－二吡啶基吡唑類衍生物、其製備方法及其在醫藥上的應用
CA3082579A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3788038B1 (en) * 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52564A (fr) * 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es) * 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents

Also Published As

Publication number Publication date
TW202233607A (zh) 2022-09-01
JP2023547194A (ja) 2023-11-09
EP4237412A1 (en) 2023-09-06
EP4237412A4 (en) 2024-04-10
KR20230098252A (ko) 2023-07-03
BR112023007912A2 (pt) 2024-01-02
US20240116900A1 (en) 2024-04-11
CA3199295A1 (en) 2022-05-05
IL302359A (en) 2023-06-01
CN116472039A (zh) 2023-07-21
WO2022089604A1 (en) 2022-05-05
AU2021372796A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
ZA202308118B (en) Cdk inhibitor
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
FI3849534T3 (fi) Yhdistelmähoidot
PH12019500025A1 (en) Cancer treatment combinations
MY201382A (en) Pde9 inhibitor and use thereof
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
NZ714963A (en) Compositions and methods for treating anemia
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2024000807A (es) Inhibidor de aak1 y uso de este.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
ZA202401684B (en) Novel parp7 inhibitor and use thereof
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
MX2025000291A (es) Compuesto heterocíclico capaz de inhibir prmt5•mta y uso del mismo
PH12021553056A1 (en) Modified release formulations and uses thereof
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
NZ751972A (en) Treatment of prurigo nodularis